nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2014 | Original Article

Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis

verfasst von: Si Guo, JingJing Xu, Rui Xue, YuQiong Liu, HaiBo Yu

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

It was reported that the nuclear receptor coactivator amplified in breast cancer1 (AIB1) could regulate cancer cell invasion and migration in a nuclear receptor signaling-independent manner. Meanwhile, the process of epithelial mesenchymal transition (EMT) is critical for tumor invasion and metastasis. The present study aimed to determine the role of AIB1 and EMT markers in human pancreatic adenocarcinoma.

Methods

AIB1, ZO-1, E-cadherin, vimentin, and N-cadherin protein expression in 76 pancreatic adenocarcinomas were assessed using immunohistochemistry and analyzed for clinicopathological significance.

Results

The frequency of AIB1 overexpression in pancreatic adenocarcinomas with lymph node metastasis is 68 % (19/28), which is significantly higher than in pancreatic adenocarcinomas without lymph node metastasis (42 %; 20/48). In addition, the frequency of low expression of E-cadherin in pancreatic carcinomas with lymph node metastasis (68 %; 19/28) was significantly higher than in tumors without lymph node metastasis (44 %; 21/48). Correlation analysis demonstrated that the overexpression of AIB1 was inversely correlated with low expression of E-cadherin in pancreatic adenocarcinomas.

Conclusion

Overexpression of AIB1 might promote invasion and metastasis of cancer cells and is associated with down-regulation of E-cadherin in pancreatic adenocarcinomas.

Li D, Xie K, Wolff R et al (2004) Pancreatic cancer. Lancet 363:1049–1057PubMedCrossRef

Laheru D, Jaffee EM (2005) Immunotherapy for pancreatic cancer—science driving clinical progress. Nat Rev Cancer 5:459–467PubMedCrossRef

Anzick SL, Kononen J, Walker RL et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968PubMedCrossRef

Yoshida H, Liu J, Samuel S et al (2005) Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Mol Cell Endocrinol 245:77–85PubMedCrossRef

Yan J, Erdem H, Li R et al (2008) Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68:5460–5468PubMedCentralPubMedCrossRef

Li LB, Louie MC, Chen HW et al (2008) Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett 261:64–73PubMedCrossRef

Qin L, Liao L, Redmond A et al (2008) The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28:5937–5950PubMedCentralPubMedCrossRef

Kuang SQ, Liao L, Zhang H et al (2004) AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 64:1875–1885PubMedCrossRef

Ying H, Willingham MC, Cheng SY (2008) The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene 27:823–830PubMedCrossRef

10.

Chung AC, Zhou S, Liao L et al (2007) Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 67:5965–5975PubMedCentralPubMedCrossRef

11.

Torres-Arzayus MI, Font de Mora J, Yuan J et al (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263–274PubMedCrossRef

12.

Torres-Arzayus MI, Zhao J, Bronson R et al (2010) Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 70:4102–4111PubMedCentralPubMedCrossRef

13.

Emadi Bayqi M, Soheili ZS, Schmitz I et al (2010) Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 26:553–567CrossRef

14.

Gnanapragasam VJ, Leung HY, Pulimood AS et al (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928–1936PubMedCentralPubMedCrossRef

15.

Ghadimi BM, Schröck E, Walker RL et al (1999) Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 154:525–536PubMedCentralPubMedCrossRef

16.

Sakakura C, Haqiwara A, Yasuoka R et al (2000) Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 89:217–223PubMedCrossRef

17.

Sakaguchi H, Fujimoto J, Sun WS et al (2007) Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J Steroid Biochem Mol Biol 104:237–240PubMedCrossRef

18.

He LR, Liu MZ, Li BK et al (2009) Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci 100:1591–1596PubMedCrossRef

19.

Wang Y, Wu MC, Sham JS et al (2002) Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346–2352PubMedCrossRef

20.

Liu MZ, Xie D, Mai SJ et al (2008) Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol 129:728–734PubMedCrossRef

21.

Qutob MS, Bhattacharjee RN, Pollari E et al (2002) Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. Mol Cell Biol 22:6611–6626PubMedCentralPubMedCrossRef

22.

Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319–8326PubMedCrossRef

23.

Klymkowsky MW, Savagner P (2009) Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol 174:1588–1593PubMedCentralPubMedCrossRef

24.

Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef

25.

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273PubMedCrossRef

26.

Cavallaro U, Christofori G (2004) Cell adhesion and signaling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118–132PubMedCrossRef

27.

Pignatelli M, Ansari TW, Gunter P et al (1994) Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 174:243–248PubMedCrossRef

28.

Cai J, Lkeguchi M, Tsujitani S et al (2001) Significant correlation between micrometastasis in the lymph nodes and reduced expression of E-cadherin in early gastric cancer. Gastric Cancer 4:66–74PubMedCrossRef

29.

Yoshida R, Kimura N, Harada Y et al (2001) The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 18:513–520PubMed

30.

Tan TK, Zheng G, Hsu TT et al (2010) Macrophage matrix metalloproteinase-9 mediates epithelial-Mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol 176:1256–1270PubMedCentralPubMedCrossRef

31.

Zhou G, Hashimoto Y, Kwak I et al (2003) Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742–7745PubMedCentralPubMedCrossRef

32.

Colo GP, Rubio MF, Nojek IM et al (2008) The p160 nuclear receptor co-activator RAC-3 exerts an anti-apoptotic role through a cyto-plasmatic action. Oncogene 27:2430–2444PubMedCrossRef

33.

Colo GP, Rosato RR, Grant S et al (2007) RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett 581:5075–5081PubMedCrossRef

34.

Henke RT, Haddad BR, Kim SE et al (2004) Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 10:6134–6142PubMedCrossRef

Titel: Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis
verfasst von: Si Guo
JingJing Xu
Rui Xue
YuQiong Liu
HaiBo Yu
Publikationsdatum: 01.04.2014
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0549-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy

Curcumin targets the AKT–mTOR pathway for uterine leiomyosarcoma tumor growth suppression

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer

Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients

Outcome of stage IB2–IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie